The LENVIMA Patient Assistance Program is for patients who need help paying for LENVIMA. This program provides LENVIMA at no cost to uninsured and financially burdened patients who meet the program eligibility criteria.* You can enroll your patients by downloading the LENVIMA Eisai Assistance Program Enrollment Form and faxing it to 1-866-613-4724 1-866-613-4724 or by calling 1-866-61-EISAI 1-866-61-EISAI. Please note that your patient’s signature is required to complete enrollment.
Full Answer
What is the Eisai Assistance Program for Lenvima?
The Eisai Assistance Program offers access and reimbursement support, including: Financial assistance information via the LENVIMA ® (lenvatinib) $0 Co-pay Program (see below for more information) The LENVIMA Patient Assistance Program for patients who need help paying for LENVIMA.
How do I apply for the Lenvima Patient Assistance Program?
The LENVIMA Patient Assistance Program provides LENVIMA at no cost to patients in need who meet program eligibility criteria.* To determine if you are eligible, download the LENVIMA Eisai Assistance Program Enrollment Form or call 1-866-61-EISAI (1-866-613-4724). Hours of operation are Monday through Friday, 8 AM to 8 PM ET.
How do I contact Eisai Medical Information?
Please contact Eisai Medical Information for any questions about our products at 888-274-2378 (8:30 AM - 5:00 PM, Eastern Time, Monday - Friday).
Can Eisai guarantee payment of any claim?
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims.
Is lenvatinib covered by Medicare?
Yes. 100% of Medicare prescription drug plans cover this drug.
Is there a generic for Lenvima?
Lenvatinib is the generic for the trade name drug Lenvima™. In some cases, health care professionals may use the trade name Lenvima™ when referring to the generic drug name lenvatinib. Drug type: Lenvatinib is a targeted therapy.
Who is the manufacturer of Lenvima?
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE FDA APPROVAL OF LENVIMA® (LENVATINIB) CAPSULES FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
How effective is Lenvima?
Lenvima has been shown to be at least as effective as the cancer medicine sorafenib at prolonging the time patients lived in one main study. The study involved 954 patients with hepatocellular carcinoma who had not previously been treated for their cancer and whose cancer could not be removed by surgery.
How much does Lenvima cost per month?
Lenvima Coupon & Prices - Cost $49 per month.
How long can you take Lenvima?
You will take Lenvima (lenvatinib) until your body no longer responds to the medication or the side effects become too severe for you to tolerate. In safety studies conducted by the manufacturer, most patients took Lenvima for 6 to 16 months for the treatment of various types of cancer.
Does Lenvima shrink tumors?
In conclusion, lenvatinib immediately shrinks tumors, the so-called ETS phenomenon. Therefore, careful attention should be paid to fistula formation from the early phase.
Is Lenvima chemo?
It is an antineoplastic (anti-cancer) drug that belongs to a class called tyrosine kinase inhibitors (TKI) of vascular endothelial growth factor (VEGF) receptors. TKIs work by inhibiting the enzyme tyrosine kinase, thus blocking cell growth and division. Lenvima is a type of chemotherapy.
Does Lenvima cause high blood pressure?
High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your health care provider should check your blood pressure regularly during treatment with LENVIMA.
Does Lenvima cause hair loss?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Hair loss.
Is Lenvima an immunotherapy?
For example, lenvatinib is used in combination with pembrolizumab (Keytruda), an immunotherapy, for the treatment of endometrial cancer.
Was lenvatinib successful?
Lenvatinib (Lenvima) alone was an effective first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC), according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium from a retrospective, real-world analysis in the United States.
When does LENVIMA go generic?
Lenvima was eligible for patent challenges on February 13, 2019. By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2035.
Does LENVIMA shrink tumors?
In conclusion, lenvatinib immediately shrinks tumors, the so-called ETS phenomenon. Therefore, careful attention should be paid to fistula formation from the early phase.
Is LENVIMA chemotherapy?
It is an antineoplastic (anti-cancer) drug that belongs to a class called tyrosine kinase inhibitors (TKI) of vascular endothelial growth factor (VEGF) receptors. TKIs work by inhibiting the enzyme tyrosine kinase, thus blocking cell growth and division. Lenvima is a type of chemotherapy.
Can I stop taking LENVIMA?
Your health care provider may choose to adjust your LENVIMA dose during treatment, stop treatment for some time, or completely stop treatment. In some cases, this may happen more than once. Keep in mind, your health care provider will tell you how much LENVIMA to take and when to take it.
How to report lenviga side effects?from eisaireimbursement.com
These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. For more information about LENVIMA, please see full Prescribing Information .
How to get full dose of lenvatinib?from drugs.com
To get a full dose, you may need to take a combination of capsules with different amounts (strengths) of lenvatinib in them. Follow your doctor's dosing instructions very carefully. Swallow the capsule whole and do not crush, chew, break, or open it.
What is lenvatinib?from drugs.com
Lenvatinib is a kinase inhibitor used to treat certain types of cancer. Kinase inhibitors are enzyme inhibitors that blocks the action of one or more protein kinases.
What should I avoid while taking lenvatinib?from drugs.com
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
What is the mechanism of action of lenvatinib?from dailymed.nlm.nih.gov
12.1 - Mechanism of Action - Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and ...
How long do you have to stop lenvatinib?from drugs.com
You may need to stop using lenvatinib for at least 1 week before surgery or at least 2 weeks after major surgery. Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin.
How to prevent diarrhea while taking lenvatinib?from drugs.com
You will need frequent medical tests and blood pressure checks. Pay special attention to your dental hygiene while taking lenvatinib. Brush and floss your teeth regularly.
How long to withhold leniva?
Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established. Osteonecrosis of the Jaw (ONJ).
How long after leniva can you stop breastfeeding?
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential.#N#No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with RCC or DTC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.#N#No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.#N#No dose adjustment is recommended for patients with DTC or RCC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe hepatic impairment. Reduce the dose for patients with DTC or RCC and severe hepatic impairment.
Does Eisai have a patient assistance program?
Eisai has established the Patient Assistance Program for patients who need help paying for LENVIMA ®. This program provides LENVIMA ® at no cost to uninsured and financially burdened patients who meet the program eligibility criteria.
What is the Eisai program?
The Eisai Assistance Program is your resource for information about coverage of LENVIMA and available financial assistance options. It will help you: Understand if your medicine is covered by insurance. Determine eligibility for assistance if you cannot afford your medication. Visit the Eisai Assistance Program.
How to contact Eisai?
Contact the Eisai Assistance Program directly at 1-866-613-4724. The Eisai Assistance Program is your resource for information about coverage of LENVIMA and available financial assistance options.
What is the Eisai program?from lenvima.com
The Eisai Assistance Program is your resource for information about coverage of LENVIMA and available financial assistance options. It will help you: Understand if your medicine is covered by insurance. Determine eligibility for assistance if you cannot afford your medication. Visit the Eisai Assistance Program.
How to contact Eisai?from lenvima.com
Contact the Eisai Assistance Program directly at 1-866-613-4724. The Eisai Assistance Program is your resource for information about coverage of LENVIMA and available financial assistance options.
How long after leniva can you stop breastfeeding?from eisaireimbursement.com
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential.#N#No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with RCC or DTC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.#N#No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.#N#No dose adjustment is recommended for patients with DTC or RCC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC or RCC and severe hepatic impairment. Reduce the dose for patients with DTC or RCC and severe hepatic impairment.
How to report lenviga side effects?from eisaireimbursement.com
These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. For more information about LENVIMA, please see full Prescribing Information .
What is lenvigam used for?from eisaireimbursement.com
LENVIMA is a prescription medicine that is used to treat certain kinds of cancer. LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
How long to withhold leniva?from eisaireimbursement.com
Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established. Osteonecrosis of the Jaw (ONJ).
What is the treatment for renal cell carcinoma?from eisaireimbursement.com
LENVIMA is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicine.
When was Eisai founded?from patientassistance.com
Eisai, Inc. was founded in 1995 as a U.S. Pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd.. Eisai, Inc. is considered to be in the top 25 pharmaceutical companies worldwide thanks to their development of the donepezil and rabeprazole molecule. Eisai, Inc. developes and produces therapies through co-promotion with other pharmaceutical companies.
How to report lenviga side effects?from eisaireimbursement.com
These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. For more information about LENVIMA, please see full Prescribing Information .
What is lenvigam used for?from eisaireimbursement.com
LENVIMA is a prescription medicine that is used to treat certain kinds of cancer. LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
Can lenviga cause kidney failure?from eisaireimbursement.com
kidney problems: Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys. increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious.
Is Lenvima safe for children?from eisaireimbursement.com
LENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery. It is not known if LENVIMA is safe and effective in children.
Does Eisai offer reimbursement?from patientassistance.com
Eisai Oncology Reimbursement Assistance Program, a patient assistance program provided by Eisai, Inc., offers the medications listed to the right at no cost to those who are eligible for the program . Eligibility is based off of the following requirements:
Does lenvigam cause rash?from eisaireimbursement.com
The most common side effects of LENVIMA in people treated for liver cancer include tiredness, decreased appetite, joint and muscle pain, weight loss, stomach (abdomen) pain, rash, redness, itching, or peeling of your skin on your hands and feet, hoarseness, bleeding, change in thyroid hormone levels, and nausea.
Warnings and Precautions
- Hypertension.In DTC, hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC, hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure ≥160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure ≥100 mmHg. In HCC, hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). …
Adverse Reactions
- In DTC, the most common adverse reactions (≥30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), an…
Use in Specific Populations
- Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential. No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CL...